Annexon, Inc. (NASDAQ:ANNX - Get Free Report) Director William H. Carson acquired 3,200 shares of Annexon stock in a transaction dated Tuesday, September 3rd. The shares were purchased at an average cost of $5.48 per share, with a total value of $17,536.00. Following the completion of the transaction, the director now directly owns 19,200 shares of the company's stock, valued at $105,216. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Annexon Stock Performance
ANNX opened at $5.59 on Thursday. Annexon, Inc. has a 52-week low of $1.57 and a 52-week high of $8.40. The firm has a market capitalization of $516.59 million, a PE ratio of -3.80 and a beta of 1.28. The business's 50-day simple moving average is $5.66 and its 200 day simple moving average is $5.48.
Annexon (NASDAQ:ANNX - Get Free Report) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.23). On average, research analysts forecast that Annexon, Inc. will post -0.97 earnings per share for the current year.
Analysts Set New Price Targets
Kamala’s Dirty Election Move… Revealed
From Paradigm Press | Ad
According to former advisor to the CIA, the Pentagon and the White House Jim Rickards…
Kamala and her puppet masters are planning this dirty election move…
Click here now and learn how to prepare.
Several research firms have recently weighed in on ANNX. Needham & Company LLC reaffirmed a "buy" rating and set a $16.00 price objective on shares of Annexon in a research report on Tuesday, August 13th. HC Wainwright reaffirmed a "buy" rating and set a $30.00 price objective on shares of Annexon in a research report on Tuesday, August 13th. Wells Fargo & Company reduced their price objective on Annexon from $12.00 to $10.00 and set an "overweight" rating for the company in a research report on Wednesday, May 15th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Annexon in a report on Wednesday, June 5th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $15.80.
Read Our Latest Report on Annexon
Institutional Trading of Annexon
Several institutional investors and hedge funds have recently bought and sold shares of the business. Maven Securities LTD bought a new stake in Annexon in the second quarter valued at approximately $170,000. Susquehanna Fundamental Investments LLC grew its position in Annexon by 385.6% during the second quarter. Susquehanna Fundamental Investments LLC now owns 163,025 shares of the company's stock worth $799,000 after buying an additional 129,455 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in Annexon by 67.5% during the second quarter. The Manufacturers Life Insurance Company now owns 157,136 shares of the company's stock worth $770,000 after buying an additional 63,330 shares in the last quarter. AQR Capital Management LLC grew its position in Annexon by 2,356.2% during the second quarter. AQR Capital Management LLC now owns 279,463 shares of the company's stock worth $1,369,000 after buying an additional 268,085 shares in the last quarter. Finally, Point72 Europe London LLP acquired a new stake in shares of Annexon in the 2nd quarter valued at $1,150,000.
Annexon Company Profile
(
Get Free Report)
Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
